TWI291957B - Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same - Google Patents

Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same Download PDF

Info

Publication number
TWI291957B
TWI291957B TW091102310A TW91102310A TWI291957B TW I291957 B TWI291957 B TW I291957B TW 091102310 A TW091102310 A TW 091102310A TW 91102310 A TW91102310 A TW 91102310A TW I291957 B TWI291957 B TW I291957B
Authority
TW
Taiwan
Prior art keywords
group
same
carbon atoms
formula
chain
Prior art date
Application number
TW091102310A
Other languages
English (en)
Original Assignee
Kotobuki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kotobuki Pharmaceutical Co Ltd filed Critical Kotobuki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of TWI291957B publication Critical patent/TWI291957B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Description

蔻0808
(R3)p 、申請專利範圍 n、P、q及r爲0、1或2之整數〕〇 2. 種以通式（Ϊ )所表不之化合物或其藥學上能容 許之鹽類之製造方法，其特徵爲，係使得以通式（π ): (H) 〔式中，A丨、A?、I及p與上述相同、X爲鹵素等之 脫離基或旋光性的磺內醯胺衍生物〕所表示之化合物，與 以通式（羾）： 、 (m) (請先閲讀背面之注意事項再填寫本頁) 、τ ·· 線 (式中A3、A4、R3及η、q、r與上述相同）所表示 之化合物’於鹼存在下加熱回流來進行史陶丁格 (Stuadinger)反應或曼尼希(Mannich)反應。 3. —種以通式（I )所表示之化合物或其藥學上能容 許之鹽類之製造方法，其特徵爲，係使得以通式（IV):
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A8B8C8D8
X 申請專利範圍 之化合物，與以通式（V): ·Α2、 (V) (式中，Α】、Α2、ρ、X及R3與上述相同）所表示之 化合物於鹼存在下反應。 4. 一種以通式（I )所表示之化合物或其藥學上能容 許之鹽類之製造方法，其特徵爲，係使得以通式（VI): (R3)q (VI) (請先閲讀背面之注意事項再填寫本頁)
(R3), •1T: 〔式中，η、p、q、r、Ai、A2、A3、A4 及 R3 與上述 相同’ Y爲旋光性的磺內醯胺衍生物〕所表示之化合物在 氫氧化鋰等鹼存在下反應來去除旋光性的磺內醯胺衍生物 成爲以通式(VI-1):
A 必 A2r^(R3)q 0¾¾ …… ^ A4 (R3)r 〔式中，η、p、q、r、Αι、A2 ' A3 ' A4 以及 R3 與上述 相同〕所表示之化合物，之後， a)於無溶劑或二氯甲烷、二氯乙烷等之溶劑中、鹵化 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公爱) A8BSC8D8 申請專利範圍 劑存在下反應； b) 於縮合劑與二氯甲烷、DMF (N，N—二甲基甲醯胺） 等之溶劑中，鹼存在下反應； c) 於BihP(第三丁基膦）、Ph3P(三苯基膦)之存在下’使 光延試劑反應； d) 於BiuP(第三丁基膦）、PbP(三苯基膦)之存在下’使 (PyS) 2反應；或是， e) 於2,6—二氯化苯甲醯氯、2,4,6—三氯化苯甲醯氯等 反應在NaH存在下反應，然後以氫氧化鈉水溶液處理； 來進行通式(VI-1)所表示之化合物之環化反應。 5. —種以通式（I )所表示之化合物或其藥學上能容 許之鹽類之製造方法，其特徵爲，係使得以通式（VI): •CR3)« (請先閲讀背面之注意事項再填寫本頁) (VI)
,^γ·α4 (R3)r 線 〔式中，η、p、q、r、Αι、A2、A3、八4、R3 以及 γ 與 上述相同〕所表示之化合物在氫氧化鋰等鹼存在下反應$ 去除旋光性的磺內醯胺衍生物成爲以通式(VI-1): 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A8 B8 C8 D8 六、申請專利範圍
〔式中，n、p、q、r、Αι、Ας、A3、At 以及 Rj 與上述 相同〕所表示之化合物之後’進行酯化成爲以通式(VI-2):
〔式中，η、p、q、r、Αι ' A2、A3、A4 以及 R3 與上述 相同，R7係甲基或乙基〕所表示之化合物，之後， a) 與LDA (二異丙醯胺鋰）或是LiHMDS〔雙（三甲 基甲矽烷基）醯胺鋰〕等鹼在溶劑中反應；或是 b) 與EtMgBr(溴化乙基鎂）、t-BuMgBr(溴化正丁基鎂) 等之格利雅試劑反應， 來進行通式(VI-2)所表示之化合物之環化反應。 6. —種以通式（VII)所表示之化合物或其藥學上能容 許之鹽類的製造方法， (請先閲讀背面之注意事項再塡寫本頁) 線 本纸張夂度適用中國國家標準(CNS)A4規格(210 X 297公楚·) 申請專利範圍 A8 B8 C8 D8
式中，A]、A〗、八4、R_3、η、p、q及r與上述相同；R? 爲單鍵(一）、_CH=HC—或一 OCH2 ; k'爲0或1〜9的整數 〕所表示之化合物或其藥學上能容許之鹽類；其特徵在於 ，係使得以通式（VEI) 7
A
(vm) 〔式中，Αι、A2、A4、R3、η、p、q及R3與上述相同 ;Z爲鹵素原子或三氟甲磺酸基等之脫離基，k'爲0或1〜 10的整數〕所表示之化合物，與以通式（IX ): R3y^R3 1^6-(012卜0人112 (式中，112及R3與上述相同，R6爲鹵素原子、一 CH CH2或-CH2〇H)所表示之化合物，在醋酸鈀以及2_ ( 三級丁基膦基）聯苯存在下進行偶合反應。 (IX) (請先閲讀背面之注意事項再塡寫本頁) 線 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) A8B8C8D8 六、申請專利範圍 7. —種降血清膽固醇組成物，係含有以通式（I )所 表示之化合物或其藥學上能容許之鹽類。 8. 如申請專利範圍第7項之降血清膽固醇組成物，係 進一步倂用/5 -內酿胺酶抑制劑。 (請先閲讀背面之注意事項再填寫本頁)
-P 、\έ 線 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
TW091102310A 2001-02-23 2002-02-08 Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same TWI291957B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001048202 2001-02-23
JP2001128031 2001-04-25

Publications (1)

Publication Number Publication Date
TWI291957B true TWI291957B (en) 2008-01-01

Family

ID=26609978

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091102310A TWI291957B (en) 2001-02-23 2002-02-08 Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same

Country Status (18)

Country Link
US (1) US7045515B2 (zh)
EP (1) EP1362855B1 (zh)
JP (1) JP4229701B2 (zh)
KR (1) KR100721639B1 (zh)
CN (1) CN1273467C (zh)
AT (1) ATE374769T1 (zh)
AU (1) AU2002237522B2 (zh)
BR (1) BRPI0206193B1 (zh)
CA (1) CA2438961C (zh)
DE (1) DE60222742T2 (zh)
DK (1) DK1362855T3 (zh)
ES (1) ES2294101T3 (zh)
HK (1) HK1060357A1 (zh)
MX (1) MXPA03005073A (zh)
PT (1) PT1362855E (zh)
RU (1) RU2301799C2 (zh)
TW (1) TWI291957B (zh)
WO (1) WO2002066464A1 (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05453B1 (et) 2001-03-28 2011-08-15 Schering Corporation Protsess asetidinoonvahehendite valmistamiseks
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
EP1682117A1 (en) * 2003-10-30 2006-07-26 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
SI1682499T1 (sl) * 2003-11-10 2008-02-29 Microbia Inc 4-biarilil-1-fenilazetidin-2-oni
PT1682499E (pt) * 2003-11-10 2007-11-05 Microbia Inc 4-biarilil-1-fenilazetidin-2-onas
EP1699759B1 (en) 2003-12-23 2010-10-20 AstraZeneca AB Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
AU2004308332B2 (en) 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
PT1756049E (pt) 2004-05-21 2007-12-17 Sanofi Aventis Deutschland Processo para a preparação de derivados de 1,4-difenilazetidinona
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
MX2007006695A (es) 2004-12-03 2007-08-14 Schering Corp Piperazinas sustituidas como antagonistas de cb1.
TW200726746A (en) 2005-05-06 2007-07-16 Microbia Inc Processes for production of 4-biphenylylazetidin-2-ones
MX2007014172A (es) * 2005-05-11 2008-04-02 Microbia Inc Procedimiento para la produccion de 4-bifenililacetidina-2-onas fenolicos.
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
AU2006249905A1 (en) * 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
CN101198338A (zh) * 2005-06-15 2008-06-11 默克公司 抗高胆固醇血化合物
KR20080021082A (ko) 2005-06-20 2008-03-06 쉐링 코포레이션 히스타민 ｈ3 길항제로서 유용한 피페리딘 유도체
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
AR057072A1 (es) 2005-06-22 2007-11-14 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
NZ566877A (en) 2005-09-29 2010-05-28 Sanofi Aventis Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
NZ569814A (en) * 2006-01-18 2011-10-28 Schering Corp Cannibinoid receptor modulators
JP4880348B2 (ja) * 2006-04-25 2012-02-22 壽製薬株式会社 アズレン誘導体及びそれを有効成分とする血清コレステロール低下剤
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
CA2663500A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
CN101541805A (zh) 2006-09-15 2009-09-23 先灵公司 用于治疗疼痛和脂代射紊乱的氮杂环丁烷和氮杂环丁酮衍生物
JP2010503677A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 脂質代謝の障害を治療するためのアゼチジノン誘導体
US20080070890A1 (en) * 2006-09-15 2008-03-20 Burnett Duane A Spirocyclic Azetidinone Compounds and Methods of Use Thereof
EP2124549A4 (en) * 2006-12-20 2010-01-20 Merck & Co Inc ANTIHYPERCHOLESTERINAMIC COMPOUNDS
DE102007005045B4 (de) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
MX2010000334A (es) * 2007-06-28 2010-04-22 Intervet Int Bv Piperazinas sustituidas como antagonistas de cannabinoides 1.
CA2694264A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
CA2754384A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) * 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
US8785608B2 (en) 2009-08-26 2014-07-22 Sanofi Crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
CN104860980B (zh) * 2015-04-23 2018-06-19 上海弈柯莱生物医药科技有限公司 一种用于合成依折麦布的中间体及其制备方法和应用
US11504390B2 (en) 2019-03-20 2022-11-22 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (SREBF1) inhibitors
WO2020191163A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5857360A (ja) * 1981-10-01 1983-04-05 Ajinomoto Co Inc アゼチジノン誘導体
HUT67341A (en) * 1991-07-23 1995-03-28 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof
US5412092A (en) * 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
TW448181B (en) * 1995-10-31 2001-08-01 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU7472896A (en) * 1995-11-02 1997-05-22 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-({phenyl or 4-fluorophenyl})-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinon
CZ20031733A3 (cs) * 2000-12-21 2003-09-17 Aventis Pharma Deutschland Gmbh Difenylazetidinonové deriváty a farmaceutické prostředky s jejich obsahem

Also Published As

Publication number Publication date
RU2301799C2 (ru) 2007-06-27
ATE374769T1 (de) 2007-10-15
JPWO2002066464A1 (ja) 2004-06-17
HK1060357A1 (en) 2004-08-06
DK1362855T3 (da) 2008-01-28
DE60222742T2 (de) 2008-07-17
US20040063929A1 (en) 2004-04-01
RU2003128424A (ru) 2005-01-27
CA2438961C (en) 2010-02-16
AU2002237522B2 (en) 2007-08-02
JP4229701B2 (ja) 2009-02-25
DE60222742D1 (de) 2007-11-15
CN1273467C (zh) 2006-09-06
EP1362855A4 (en) 2005-02-23
US7045515B2 (en) 2006-05-16
EP1362855B1 (en) 2007-10-03
KR100721639B1 (ko) 2007-05-23
EP1362855A1 (en) 2003-11-19
CN1492865A (zh) 2004-04-28
ES2294101T3 (es) 2008-04-01
CA2438961A1 (en) 2002-08-29
KR20030076690A (ko) 2003-09-26
PT1362855E (pt) 2007-12-04
BRPI0206193B1 (pt) 2016-05-24
BR0206193A (pt) 2004-02-03
WO2002066464A1 (en) 2002-08-29
MXPA03005073A (es) 2003-09-05

Similar Documents

Publication Publication Date Title
TWI291957B (en) Beta-lactam compounds, process for repoducing the same and serum cholesterol-lowering agents containing the same
EP3478674B1 (en) 4,6-diaminoquinazolines as cot modulators and methods of use thereof
TW548274B (en) Dihydropyrimidines having hepatitis B therapeutic efficacy
BR112017002970B1 (pt) Novas piridazonas e triazinonas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
JP6063934B2 (ja) 統合失調症、認識障害及び疼痛などの疾患の治療におけるｄ−アミノ酸オキシダーゼ（ｄａａｏ）阻害剤としての、５−又は６−置換３−ヒドロキシ−２（１ｈ）−ピリジノン
JPS63139182A (ja) チアゾリジンジオン誘導体の製造法
UA63875C2 (en) Substituted imidazoles, a process for the preparation thereof, a pharmaceutical composition based thereon and a method for treatment
CN101316829A (zh) 具有crth2受体活性的噁二唑衍生物
EP1396487A1 (en) Phenylpyridine carbonyl piperazine derivative
JPS5976059A (ja) 環状イミド誘導体及びその酸付加塩
TW399051B (en) A novel benzoazine thiazolidinedione derivative and pharmaceutical composition for reducing blood glucose
IL170093A (en) Method for preparing acid addition salts of polyacidic basic compounds
JPH08506354A (ja) ５−［２−（４−（ベンゾイソチアゾール−３−イル）−ピペラジン−１−イル）エチル−６−クロロ−１，３−ジヒドロ−インドール−２−オンの製造方法及び製造用中間体
CA1172636A (en) Thiazolidinylalkylene piperazine derivatives
JP2005517643A5 (zh)
CN102482264B (zh) 2-氨甲酰基-7-哌嗪基-苯并呋喃衍生物774
JP6758374B2 (ja) Ｉｄｈ２突然変異を標的とする抗腫瘍化合物及びその使用方法
CN1072655C (zh) 新型杂环氨甲基化合物,其制备方法及含有它们的药物组合物
TW450954B (en) Phenylsulfonamide-phenylethylamines useful as dopamine receptors
JPH02289556A (ja) オキサゾール化合物
TW593294B (en) Polycyclic thiazole systems having anorectic activity, processes for their preparation and pharmaceutical composition comprising these compounds
KR840003250A (ko) 3-(1h-테트라졸-5-일)-4-(3h)-퀴나졸리논의 제조방법
NZ201158A (en) Spirothiazolidinedione derivatives and pharmaceutical compositions
JPS6153268A (ja) アントラニルアミド誘導体
JP3760484B2 (ja) チエノ［２，３−ｄ］ピリミジン−４−オン誘導体

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees